Greg Flynn, Ashfield Engage


Why agility is the key to navigating the fast-changing healthcare landscape

Outlining the key digital trends accelerated by the transformed healthcare landscape in 2021—and their impact on pharma commercialization strategies going forward

Melonie Warfel, Model N


More changes ahead: Biopharma market trends for rest of 2021

The evolving topics to keep a close watch on in the coming months

Graham Rapier, Aktana


'Next-Best-Action' for Data Analytics

How to make commercial AI actionable in the last mile, helping to better realize data science investment and improve customer engagement

Marie Flanagan


The Challenges of Safety Risk Detection: The Automation Solution

If there’s anything we learned from the pandemic, it’s the critical need to analyze patient outcome data in real time to stay informed on the safety and efficacy of treatments in the real world

Abhishek Sinha, Accenture


A Pharma Pricing and Agreements Primer in Today's Complex Landscape

In order to provide both profitability and medication access, a balancing act is required.

Will Robinson


What Goes into Planning LogiPharma Europe?

A dive into the intricacies of how to ensure a long-running event stays fresh and relevant to the needs of the pharmaceutical industry.

Dan Rizzo, Veeva


New Blueprint for HCP Relationships

Three keys to achieving digital excellence in the next normal, where a hybrid commercial model will be the standard for physician engagement

Eric Bennett, Duke Energy


Critical power: The lifeline for pharmaceutical manufacturing

Outlining the business-vital areas pharma organizations should consider today in energy risk management, including the value of resiliency



The Cultural Divide Between IT & OT Puts Critical Operations at Risk.

Sponsored by Dragos, the Ponemon Institute’s report on the State of Industrial Cybersecurity finds that cultural and technical differences between traditional IT best practices and what is possible in OT increases an organization’s risk for costly cyber incidents – and the average cost to detect, investigate, and remediate an event.

Sonia T. Oskouei and Jeff Baldetti, Cardinal Health


Key learnings to support biosimilar commercialization in the US

Taking cues from launches so far in oncology and rheumatology, three important considerations for biosimilar marketability are outlined

Rohit Gupta


Transforming the Patient Hub into a Hub of Patient Centricity

Methods that pharma companies can use to make the hub more personalized and experiential.

Bruce Feinberg


Getting to answers about Biogen’s Aduhelm

Exploring RCT, RWE and alternative study designs as a path forward

Prof. Dr. Yvonne Ziegler and Dr. Vincenzo Uli


Ensuring Compliance and Quality of Pharmaceutical Transport

For pharma companies, an investment in a digital risk management tool is worth considering if they want to meet the European Union's regulatory requirements for pharmaceutical transport and wholesalers

Groovy Singh


The Case for Domestic Sourcing to Establish Reliable Pharmaceutical Supply Chains in the United States

Reliance on foreign imports means that disruptions in the supply chain can profoundly impact the ability of individuals in the United States to get access to the medications they need.

Alisa Hummings and Simon Johns, IQVIA


Aligning Medical Information and PV

As companies seek interoperability across their organizations, a joint approach to medical information and local pharmacovigilance may deliver future benefits

Anne Marie Robertson and Ellen Cappellino


A New Approach to the Commercialization Challenges Facing the Oncology Industry

By 2024 oncology therapeutic sales will hit $250 billion worldwide, and there will be more than 22 million cancer survivors. But commercializing how these critical therapies come to market to help patients hasn’t changed much in the past 20 years. The industry must do more, write Anne Marie Robertson and Ellen Cappellino

Gregg Fisher and Anca Davies-Rusu


Making Sustainable Omnichannel Change

A look into ways to approach change management using three factors.

Dae Y. Lee, Esq.


The Consolidated Appropriations Act and PBM Transparency

New federal law introduces significant changes in the design of pharmacy benefit plans with aims to level the playing field between PBMs and their employee healthcare benefit plan clients.

Thom Stambaugh, RPh


Breaking the Chains of Opioid Addiction: The Promise of Long-Acting Injectables

As providers and healthcare professionals recognize the potential of long-acting injectables to fight the opioid epidemic, many are actively transitioning from oral options to injectables.

Amaury Jeandrain


How Digital Twins Drive Sustainability in Clinical Supply Planning

Digital twins allow the industry to integrate sustainable practices and supply chain efficiency solutions while ensuring patient safety.

Greg Hookings


Unlocking Pharma 4.0 Through Edge Computing

Creating a meaningful digital transformation requires pharmaceutical manufacturing companies to incorporate the right technologies, processes, and systems to reach their fullest potential.

Joel Wayment and Jason Cook, Cardinal Health


Building the Cold Chain of the Future

With today's greater combination of technology and know-how, we must design new ways to handle sensitive pharmaceuticals—and do it together

Ben Beckley, EmerGENE


Cell and gene therapy success: Overcoming patient and provider apprehension

The benefits of establishing an in-depth go-to-market commercialization strategy for a new CGT in the beginning of clinical trials

Ariel Katz, H1


What’s Next for Med Tech?

Four trends shaping healthcare in 2022 and beyond

Brad Klaus, FourKites


How 3PLs Can Up Their Pharma Game

The growing complexity and demand in distribution amid the pandemic present unique technology opportunities for third-party logistics providers



COVID-19 Vaccine Distribution System

Delivering COVID-19 vaccines to 7.8 billion people was a daunting challenge that stretched supply chains past their limits. This white paper dives into vaccine distribution plans and what vaccine manufacturers, distributors and administrators can take away from this monumental time in both the industry and history. Learn how temperature indicators and monitoring solutions played an essential role in the administration of the COVID-19 vaccine.

Frits Stulp


Harnessing the Potential of Data to Deliver the Future of Healthcare

Faster approvals, more accurate and timely medicines monitoring—all enabled by harmonized, consistent and reliable data—will drive improved patient outcomes.

© 2024 MJH Life Sciences

All rights reserved.